Besunyen Holdings Company Limited (“BESUNYEN”) released its unaudited interim results for the six months ended 30 June 2026.

Financial Performance • Revenue rose 17.70% year on year to RMB 304.84 million, driven mainly by a 43.80% surge in sales of the core “Four Teas” range. • Gross profit advanced 33.77% to RMB 237.38 million; gross margin expanded to 77.9% (1H25: 68.6%) on a richer product mix and lower procurement costs for weight-loss medicines. • Total operating expenses grew 31.73% to RMB 216.70 million, led by higher marketing and promotion outlays (+55.26% to RMB 164.91 million) as the company unified online and offline agency operations and stepped up e-commerce spending. • Operating profit increased 45.23% to RMB 23.95 million; profit before tax reached RMB 24.32 million (+18.39%). • Net profit / total comprehensive income attributable to owners rose 21.48% to RMB 15.07 million; basic and diluted EPS were RMB 0.12 (1H25: RMB 0.10). • No interim dividend was declared.

Segment Highlights • Tea products: Revenue RMB 209.11 million (+30.93%); accounted for 68.6% of total. Sales benefited from price recovery in traditional OTC channels and strong e-commerce demand. • Weight-loss & other medicines: Revenue edged down 3.54% to RMB 95.73 million, reflecting a slight volume decline. • Other health foods and medicines fell 26.81% to RMB 25.70 million amid strategic refocus on core categories.

Cash Flow & Balance Sheet • Operating cash inflow improved to RMB 45.04 million (1H25: RMB 30.99 million). • Cash and cash equivalents stood at RMB 218.86 million at 30 June 2026 (31 Dec 2025: RMB 177.93 million). • The group remains debt-free; gearing ratio was 20.5%. • Financial assets at fair value through profit or loss totalled RMB 145.56 million, including RMB 86.51 million invested in Central China Dragon Global Opportunity Fund SP6 (“GOSP6”).

GOSP6 Redemption Update BESUNYEN submitted a full redemption notice for its HKD 100 million investment in GOSP6 in March 2025. To date, only 10% of the principal has been returned. Repeated formal demands have been issued to the fund manager since December 2025; management continues to pursue full cash recovery.

Operational Developments • Integrated marketing: Four regional agencies merged into a single operating entity, standardising pricing and promotion strategies. • E-commerce: 69 online stores across 20 platforms; expanded presence on Douyin, Kuaishou and other new-retail channels. • R&D focus on health-food compliance renewal and new product innovation; secured a patent for a uric-acid-lowering composition. • International business restructuring towards a B2B-led, brand-driven model under the “Bessence” label.

Outlook Management plans to leverage China’s “Weight Management Year” policy, deepen omni-channel integration, advance product pipeline compliance, and intensify brand rejuvenation to sustain growth while seeking resolution of the outstanding GOSP6 redemption.